BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8467497)

  • 1. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
    Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel.
    Yeh CS; Wang JY; Wu CH; Chong IW; Chung FY; Wang YH; Yu YP; Lin SR
    Int J Oncol; 2006 Feb; 28(2):411-20. PubMed ID: 16391796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
    Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
    Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein.
    Huber K; Kirchheimer JC; Ermler D; Bell C; Binder BR
    Cancer Res; 1992 Apr; 52(7):1717-20. PubMed ID: 1372529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
    Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
    Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arginase as a marker of cancerogenesis. III. Comparison of arginase activity with CEA and Ca 19-9 in liver metastases of colorectal cancer].
    Porembska Z; Skwarek A; Chrzanowska A; Mielczarek M; Nyckowski P; Barańczyk-Kuźma A
    Pol Merkur Lekarski; 2004 Jan; 16(91):31-3. PubMed ID: 15074017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the probability of cancer with several tumor markers in patients with colorectal disease.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Oncology; 2004; 66(4):296-302. PubMed ID: 15218297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
    Grotowski M
    Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.